Johnson & Johnson (JNJ) reported Q2 2025 financial results before market open.
The company posted revenue of $23.74 billion, surpassing estimates of $22.85 billion and marking a 5.7% increase from $22.45 billion a year ago.
Adjusted earnings were $2.77 per share, beating estimates of $2.68 but down 1.8% compared to $2.82 in the prior year. For FY 2025, earnings outlook is revised to $10.80 to $10.90, above the estimate of $10.62.
Revenue outlook for FY 2025 is also raised to $93.20 billion to $93.60 billion, exceeding the estimate of $91.40 billion.
Earnings Insight
| Date | Time | Symbol | company_name | Period | Metric | Estimate | Actual | Surprise | YrAgo | Growth | sector_industry |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 07/16/2025 | BMO | JNJ | Johnson & Johnson | Q2 2025 | EPS | 2.68 | 2.77 | 3.36 | 2.82 | -1.80 | |
| 04/15/2025 | BMO | JNJ | Johnson & Johnson | Q1 2025 | EPS | 2.60 | 2.77 | 6.54 | 2.71 | 2.20 | Healthcare / Drug Manufacturers—General |
| 01/22/2025 | BMO | JNJ | Johnson & Johnson | Q4 2024 | EPS | 2.01 | 2.04 | 1.49 | 2.29 | -10.90 | Healthcare / Drug Manufacturers—General |
| 10/15/2024 | BMO | JNJ | Johnson & Johnson | Q3 2024 | EPS | 2.21 | 2.42 | 9.50 | 2.66 | -9.00 | Healthcare / Drug Manufacturers—General |
| 07/17/2024 | BMO | JNJ | Johnson & Johnson | Q2 2024 | EPS | 2.70 | 2.82 | 4.44 | 2.80 | 0.70 | Healthcare / Drug Manufacturers—General |